Eurobio Scientific team
Webinars
By Frédéric Le Gal, Deputy Head of the National Reference Center for Hepatitis Delta, Clinical Microbiology Laboratories – DMU BIOPHARES (Avicenne Hospital – GHU Paris Seine Saint Denis – Bobigny- France)
The recent G-BA decision raises key questions for clinical practice, especially in node-positive breast cancer.Experts Prof. Marcus Schmidt and Prof. Hans-Ulrich Schildhaus discuss evidence, guidelines, and patient impact.
This session takes a patient-centric look at how clinical, pathological, and genomic markers come together to inform long-term risk in ER+/HER2- breast cancer. Dr. Jessica Leitsmann explored what really matters in day-to-day practice — especially beyond the critical 5-year mark and how prognostic tools can support truly individualized treatment strategies.
Catch up on our webinar exploring how gene expression testing could advance care for premenopausal breast cancer patients. Experts PD Dr. med. Evelyn Klein and Prof. Michalis Kontos, PhD shared insights on therapy selection, guidelines and validation data for premenopausal patients.
As part of the training conference of the Austrian Society of Urology and Andrology, Univ.-Prof. Dr. Isabel Heidegger-Pircher, Prim. Doz. Dr. Martin Marszalek, and OÄ Dr. Ludmilla Zahlbruckner discussed the current state of personalized diagnostics in prostate cancer and provided valuable insights from their clinical practice.
Watch back the webinar from November 19, 2024, covering what’s new for high-risk early breast cancer patients in 2024. We discussed the potential future role of gene expression signatures in identifying candidates for the latest therapy options. Top experts Prof. Michael Untch and Prof. Frédérique Penault-Llorca presented the latest advancements, including insights into EndoPredict’s role and findings from the UNIRAD and NATALEE studies.
On the occasion of the 43rd Senology Congress, which took place from June 6–8, 2024, in Dresden, we warmly invited all participants to our lunch symposium entitled “LoE 1A – Therapy Decisions with EndoPredict – Current Data and Case Examples.”
The session was moderated by Prof. Dr. Michael Untch from Helios Klinikum Berlin-Buch.
Prof. W. Jacot, Dr. P.-J. Lamy, Dr. C. Villanueva, and Dr. O. Haddad discussed the following topics: the value of a second-generation test and the impact of analytical reliability on patient management, as well as the prognostic and predictive performance of EndoPredict in real-world studies.
Clinical cases were also presented, demonstrating the usefulness of EndoPredict in postmenopausal, node-negative (N0) and node-positive (N+) patients.
We were there when Prof. Marion Kiechle and Dr. Evelyn Klein from the Technical University of Munich presented the latest prospective real-world data from two German studies on the prognostic properties of EndoPredict and its ability to predict the benefit of chemotherapy.
Don’t miss the opportunity to revisit our ESMO 2023 Industry Satellite Symposium, where Dr. Evelyn Klein shared the latest prospective real-world data demonstrating the predictive and prognostic value of a second-generation test for early breast cancer.
The session also featured an interactive case discussion of a G2, node-positive early breast cancer patient, providing practical insights into how the test can support personalized therapy decisions.
How do genetic and genomic tests shape patient management, prognosis, and theranostics in France?
Watch our plenary session to explore the latest scientific updates and discover how our innovative genomic tests are transforming clinical decision-making in breast and prostate cancer. Learn how precision testing supports more personalized treatment strategies and improves outcomes for patients across France.
Prof. Michael Untch from HELIOS Clinic Berlin-Buch presents three clinical cases of ER+, HER2- breast cancer patients and how EndoPredict guided treatment decisions.
During the session, Dr. Anastasia Constantinidou shared compelling clinical validation data demonstrating how EndoPredict provides reliable prognostic information for premenopausal women with early breast cancer. Her presentation underlined the test’s strong evidence base and its value in guiding individualized treatment strategies.
Discover expert insights from Stuttgart, where Prof. Michael Untch, Dr. Marcus Schmidt, Dr. Rebecca Leitsmann, and Dr. Christopher Poremba discuss how EndoPredict supports informed chemotherapy decisions in breast cancer — including in premenopausal women and patients with node-positive disease.This engaging session highlights how EndoPredict helps physicians tailor treatment strategies based on robust clinical evidence and individualized risk assessment.
